NHS Fetal Anomaly Screening Programme Marie Coughlin Screening Lead January 25 th 2010.

Slides:



Advertisements
Similar presentations
Examples of Sound Screening:
Advertisements

Health Technology Assessments What are they and how are they produced? Karen Ritchie, Senior Health Services Researcher.
SOUTH AUSTRALIAN MATERNAL SERUM ANTENATAL SCREENING (SAMSAS© ) PROGRAM
SOCIAL IMPLICATIONS OF GENETIC PRENATAL SCREENING IN PREGNANCY.
Screening “the systematic application of a test procedure to identify individuals at sufficient risk to warrant diagnostic investigations” CVS 12wks Amniocentesis.
Care of the pregnant woman Year 2 Lent term. The Case 38 year old booked at 12 weeks gestation in the antenatal clinic Expecting her third baby 1 st baby.
Antenatal Screening Mehreen Yousaf GP STS.
28 January 2010 Donna Kirwan National Projects Officer to Weeks Fetal Anomaly Scan National Standards for England ‘Into the next decade’
Second-trimester maternal serum screening
Opportunity for Choice in the National Down’s Syndrome Screening Programme (NDSSP) Presented by: Nancy L. Chung.
BROWN Prenatal Screening for Trisomy 21: Recent Advances and Guidelines Jacob Canick, PhD Alpert Medical School of Brown University Women & Infants Hospital.
NHS Blood Spot Screening Programme Marie Coughlin Screening Lead July 26 th 2010.
Genetic screening.
NHS Newborn Hearing Screening Programme Marie Coughlin Screening Lead May 24 th 2010.
Genetics and Primary Care
Prenatal Genetics OG Supplemental Information Drs. Deborah Driscoll and Michael Mennuti.
2 cases of congenital abnormality Lent term year 1.
Screening for fetal Down’s Syndrome – Improving efficacy and efficiency.
NON – INVASIVE PRENATAL TESTING
Enhanced Prenatal Screening Program
Biochemical tests and ‘marker chemicals’
IN THE NAME OF GOD. CRITICALLY APPRAISED TOPIC If there is a Non-invasive prenatal testing for aneuploidies with low FPR at first trimester? If we can.
Pregnancy & Newborn Screening Developments
Ultrasound imaging.
First Trimester Screening
Routine Anomaly Scan Ilse Erasmus.
Pregnancy Screening Pathway
Objectives Goals of the week scanGoals of the week scan Fetal nuchal translucency in the detection of aneuploidyFetal nuchal translucency in.
What CARs can tell us about screening programmes & their population effects: a model for trisomy 21 Ann M Tonks (WMCAR PHE), Adam S Gornall (The Shrewsbury.
Module One: Introduction to the California Prenatal Screening Program
First and Early Second Trimester Diagnosis of Fetal Heart Disease 성균관의대 소아과 삼성제일병원 진단방사선과 민 지 연.
產科常見檢查 R 4 蔡曉文. Screening for neural tube defects and Down syndrome Screening: identifies individuals whose risk is high for further evaluation. Screening:
National Women’s Screening for Aneuploidy Dr Emma Parry CMFM Clinical Director Maternal-Fetal Medicine National Women’s Health.
In the name of god First Trimester Screening Dr.M.Moradi.
Public Health England: opportunities for better coverage? Professor John Newton, Chief Knowledge Officer, Public Health England.
Maternity Framework Antenatal Access Target and Outcome Measures Data Theme Work Stream Women and Children’s Health Information Programme Lindsay Mathie.
Prenatal Diagnosis of Congenital Malformations for Undergraduates
ACB Training Course- Plymouth Down’s syndrome screening David Worthington (Laboratory Advisor - National Screening Programme)
Pregnancy & Newborn Screening Developments. What is screening? Screening is: “a public health service in which members of a defined population, who do.
Vajiheh Marsoosi, M.D Associate Professor of TUMS Shariati Hospital.
Obstetric Ultrasound + Fetal Medicine Annual report.
The Role of Prenatal screening as part of Routine Obstetric Care
TEMPLATE DESIGN © Reduced Fetal Movements as a Predictor of Fetal Compromise Dr. Meenu Sharma Lancashire Teaching Hospital.
Intro Until recently, couples had to choose between taking the risk or considering other options Over the past three decades, prenatal diagnosis-the ability.
HIGHER HUMAN BIOLOGY Unit 2 Physiology and Health 1. Ante-natal Screening.
Genetic Testing in Pregnancy Lisbeth M. Lazaron, MD March 2013.
Fetal Diagnosis & Counseling of Pregnancy Options.
UOG Journal Club: January 2016 Clinical implementation of routine screening for fetal trisomies in the UK NHS: cell-free DNA test contingent on results.
Croydon Health Services
FASP Fetal Cardiac Ultrasound Education in UK
Diagnostic testing for Down syndrome
Figure 1: Classification of CNS abnormality (%)
UOG Journal Club: January 2016
Intro Until recently, couples had to choose between taking the risk or considering other options Over the past three decades, prenatal diagnosis-the.
A Commissioner’s Perspective
Antenatal Screening Rebecca Sykes.
Aneuploidy and NTD screening
Jeffrey A. Kuller, MD; Sean C. Blackwell, MD
Diagnostic testing for Down syndrome
Implementation of Non Invasive Prenatal Test (NIPT) as a contingency test in Wales Presented by: Sharon Hillier/ Director of Screening Division, Public.
غربالگری ناهنجاریهای جنین
guidance on antenatal screening
Diagnostic testing for Down syndrome
Ultrasound in fetal screening ( Down syndrome,…)
NON – INVASIVE PRENATAL TESTING
IN THE NAME OF GOD First trimester screening for aneuploidy
NHS Sickle Cell & Thalassaemia Screening Programme
NHS Infectious Diseases in Pregnancy Screening Programme
Diagnostic testing for Down syndrome
Presentation transcript:

NHS Fetal Anomaly Screening Programme Marie Coughlin Screening Lead January 25 th 2010

Today’s Session First of 6 Antenatal & Newborn sessions throughout 2010 Same format will be used – feedback on this would be useful

Reasons for Today’s Session As a result of ChaMPs commissioned review of screening A need to further engage public health in Antenatal & Newborn Screening Programmes At the request of public health screening leads Part of C&M Screening Action Plan Thought it useful to invite commissioners also

Aim of the Session To increase knowledge base within public health

Session Format Overview of UK NSC/NWSHA structure Overview of Fetal Anomaly Screening Review of patient pathway Data and QA Future developments Questions/comments

Overarching Structure UK NSC oversees 6 Antenatal & Newborn Screening Programmes SHA coordinators with regional and national role NWSHA coordinator jobs out to advert UK NSC has defined accountability & governance structure for SHA, PCT and provider

Purpose of Fetal Anomaly Screening Aim to offer women 2 ultrasound tests at weeks and weeks of pregnancy First scan for dating and pregnancy viability Second scan screens for major structural anomalies Down’s Syndrome Screening Programme now part of Fetal Anomaly Screening Programme Screens for down’s syndrome between weeks depending on local screening strategies

Cont… Aspires to give women an informed choice Does not screen for all conditions For down’s syndrome only gives an indication of risk, does not confirm Unlike other screening programmes, emphasis not on high uptake rates

Cont... Conditions screened for: — Alobar Holoprosencepathy (HPE) — Anencephaly — Bilateral Renal Agenesis — Cleft Lip/Palate — Congenital Diaphragmatic Hernia (CDH) — Congenital Heart Disease — Down’s Syndrome

Cont… Conditions screened for: — Edward’s Syndrome (Trisomy 18) — Exomphalos (Omphalocele) — Gastroschisis — Lethal Skeletal Dysplasia — Spina Bifida — Trisomy 13 (Patau’s Syndrome)

Patient Pathway…

NHS Fetal Anomaly Screening Programme (FASP) Rebecca Till Screening Midwife Macclesfield District General Hospital 26th January 2010

Aim Programme breakdown Strategies & Tests Pathways

Fetal Anomaly Screening Programme UK National Screening Programme Chromosomal (Down’s Syndrome Screening) Equality of access Equitable Service Structural ( Week anomaly scan)

Down’s Syndrome Screening Recommendations 75% detection rate (DR) for 3% false positive (FP) 90% detection rate (DR) for 3% false positive Benchmark timeframe - April 2010

Screening Strategies 1st Trimester Combined Quadruple Test

1st Trimester Combined Biochemical markers in maternal serum (10-14 weeks) BhCG PAPPA-A 87%DR - 3%FPR (1:150) Nuchal Translucency Scan ( weeks)

The Quadruple Test (2nd Trimester) weeks Gestation Maternal Age Ethnicity Smoking Weight 84% DR - 5% FPR PAPP-A Alpha-feta Protein BhCG Unconjugated Oestriol PAPP-ABhCG Alpha- feta Protein Unconju- gated Oestriol

PAPP-A Fetal Anomaly Ultrasound Aims & Objectives Verbal Consent Dating & Viability (8+ weeks) Structural Anomalies ( weeks) Screening Choices Management and Termination Options Two Ultrasound Scans

Fetal Anomaly Ultrasound Abnormalities Development Show fetus/heartbeat Listed anatomy Measurements Discuss results Printed handout

Patient Pathway and Timelines Screening Timeline Pathway for Trisomy 21 Screening Pathway for raised NT > 3.5mm Pathway for Fetal Anomaly Screening

Conclusions Robust Implications on Implementation Resources

Data, Performance & QA Very difficult to obtain data – not held centrally Trusts required to produce annual report QA for laboratories Developing QA for the rest of the service – NW coordinator roles will aid this

Future Developments 1 st trimester screening for Down’s Syndrome to be implemented by April 2010 — C&M PCTs not on target for this QA function to be developed further I.T. system to improve data collection to be developed

Questions/Comments How/who monitors annual reports within PCT organisations? How can we achieve 1 st trimester screening by April 2010? With regard to QA, how do we assure our Boards that local programmes run satisfactorily?

My Questions Did you find this session useful? What will you do differently as a result of this session?

Thank You